Early Stage Bladder Cancer: Do Pathology Reports Tell Us What We Need to Know? - 19/04/17
, Erik A. Pattison a, b, Daniel W. Denhalter e, f, Olga V. Patterson e, f, Scott L. DuVall e, f, John D. Seigne b, c, Douglas J. Robertson a, d, Brenda Sirovich a, d, Philip P. Goodney a, dAbstract |
Objective |
To assess a large national sample of bladder cancer pathology reports to determine if they contained the components necessary for clinical decision-making.
Methods |
We examined a random sample of 507 bladder cancer pathology reports from the national Department of Veterans Affairs Corporate Data Warehouse to assess whether each included information on the 4 report components explicitly recommended by the College of American Pathologists' protocol for the examination of such specimens: histology, grade, presence vs absence of muscularis propria in the specimen, and microscopic extent. We then assessed variation in the proportion of reports lacking at least 1 component across Department of Veterans Affairs facilities.
Results |
One hundred eight of 507 reports (21%) lacked at least 1 of the 4 components, with microscopic extent and presence vs absence of muscularis propria in the specimen most commonly missing (each in 11% of reports). There was wide variation across facilities in the proportion of reports lacking at least 1 component, ranging from 0% to 80%.
Conclusion |
One-fifth of bladder cancer pathology reports lack information needed for clinical decision-making. The wide variation in incomplete report rates across facilities implies that some facilities already have implemented best practices assuring complete reporting whereas others have room for improvement. Future work to better understand barriers and facilitators of complete reporting may lead to interventions that improve bladder cancer care.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: Florian R. Schroeck is Site PI (without any compensation) for the Phase III Trial of Vicinium (Viventia Biotech); and has received research funding from the U.S. Department of Veterans Affairs, Conquer Cancer Foundation, and American Cancer Society. Scott L. DuVall has received research grants from the following for-profit organizations: Amgen Inc., AbbVie Inc., Anolinx LLC, AstraZeneca Pharmaceuticals LP, F. Hoffmann-La Roche Ltd, Genentech Inc., Genomic Health, Inc., Gilead Sciences Inc., HITEKS Solutions Inc., LexisNexis Risk Solutions, Merck & Co., Inc., Mylan Specialty LP, Northrop Grumman Information Systems, Novartis International AG, PAREXEL International Corporation, and Shire PLC through the University of Utah or Western Institute for Biomedical Research. John D. Seigne is an owner of 100 shares of common stock of Johnson & Johnson. The remaining authors declare that they have no relevant financial interests. |
|
| Funding Support: FRS is supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, VISN1 Career Development Award, by a pilot grant from the American Cancer Society (IRG-82-003-30), by a Conquer Cancer Foundation Career Development Award, and by the Dow-Crichlow Award of the Department of Surgery at the Dartmouth-Hitchcock Medical Center. PPG is supported by a grant from the FDA (U01FD005478-01, Sedrakyan = PI). |
|
| Author Contributions: Conceptualization (FRS, DJR, BS, PPG), methodology (FRS, DWD, OVP, SLD), software (DWD, OVP, SLD), validation (FRS, EAP, DWD, OVP, SLD), formal analysis (FRS), investigation (FRS, EAP, DWD, OVP, JDS), resources (FRS, SLD, BS, PPG), data curation (SLD), drafting (FRS) and editing (all authors) of manuscript, visualization (FRS), supervision (FRS, SLD, BS, PPG), project administration (FRS, SLD), and funding acquisition (FRS, PPG). |
|
| Disclaimer: The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. |
Vol 98
P. 58-63 - décembre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
